Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Weekly News Recap #Phispers
Drugs in Development
Details:
Evolocumab is a antibody drug, which is currently being evaluated in Phase I clinical studies for the treatment of undisclosed medical condition.
Lead Product(s): Evolocumab,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 22, 2026
Lead Product(s) : Evolocumab,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Evolocumab is a antibody drug, which is currently being evaluated in Phase I clinical studies for the treatment of undisclosed medical condition.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 22, 2026
Details:
Evolocumab is a antibody drug, which is currently being evaluated in Phase I clinical studies for the treatment of undisclosed medical condition.
Lead Product(s): Evolocumab,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 20, 2026
Lead Product(s) : Evolocumab,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Evolocumab is a antibody drug, which is currently being evaluated in Phase I clinical studies for the treatment of undisclosed medical condition.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
February 20, 2026
Details:
Evolocumab is a Antibody drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Coronary Artery Disease.
Lead Product(s): Evolocumab,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Antibody, Unconjugated
Sponsor: DOTTER Inc.
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 24, 2025
Lead Product(s) : Evolocumab,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : DOTTER Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Single Dose PCSK9 Inhibitor to Improve Cardiovascular Outcomes After PCI: A Pilot Study
Details : Evolocumab is a Antibody drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Coronary Artery Disease.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
July 24, 2025
Details:
YN001 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Coronary Artery Disease.
Lead Product(s): YN001,Evolocumab
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 22, 2024
Lead Product(s) : YN001,Evolocumab
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
YN001-004 in Patients With Coronary Atherosclerosis in Australia
Details : YN001 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Coronary Artery Disease.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 22, 2024
Details:
Obicetrapib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dyslipidemias.
Lead Product(s): Obicetrapib,Evolocumab
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 11, 2024
Lead Product(s) : Obicetrapib,Evolocumab
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels
Details : Obicetrapib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dyslipidemias.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 11, 2024
Details:
Evolocumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Renal Cell.
Lead Product(s): Evolocumab,Nivolumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Bristol Myers Squibb | Cancer Prevention Research Institute of Texas | US Department of Defense
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 29, 2024
Lead Product(s) : Evolocumab,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Bristol Myers Squibb | Cancer Prevention Research Institute of Texas | US Department of Defense
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Evolocumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Renal Cell.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
February 29, 2024
Details:
Evolocumab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Evolocumab,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody, Unconjugated
Sponsor: Region Stockholm
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 18, 2023
Lead Product(s) : Evolocumab,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Region Stockholm
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Evolocumab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
November 18, 2023
Details:
Evolocumab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Aortic Aneurysm, Abdominal.
Lead Product(s): Evolocumab,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody, Unconjugated
Sponsor: National Heart, Lung, and Blood Institute | Amgen Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 13, 2023
Lead Product(s) : Evolocumab,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : National Heart, Lung, and Blood Institute | Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Mechanistic Clinical Trial of PCSK9 Inhibition for AAA
Details : Evolocumab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Aortic Aneurysm, Abdominal.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
October 13, 2023
Details:
Repatha (evolocumab) inhibits PCSK9 protein and prevents it from binding to the LDL receptor (LDLR), allowing LDLR to recycle back to the liver. By inhibiting the protein, the drug increases the number of LDLRs to clear from the blood, reducing LDL levels.
Lead Product(s): Evolocumab,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Repatha
Study Phase: Approved FDFProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 01, 2023
Lead Product(s) : Evolocumab,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Amgen to Present New Repatha® (evolocumab) and Olpasiran Data at ACC
Details : Repatha (evolocumab) inhibits PCSK9 protein and prevents it from binding to the LDL receptor (LDLR), allowing LDLR to recycle back to the liver. By inhibiting the protein, the drug increases the number of LDLRs to clear from the blood, reducing LDL level...
Product Name : Repatha
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 01, 2023
Details:
Evolocumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hyperlipoproteinemia Type II.
Lead Product(s): Evolocumab,Rosuvastatin Calcium,Ezetimibe
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Antibody, Unconjugated
Sponsor: Daewoong Pharmaceutical
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 22, 2022
Lead Product(s) : Evolocumab,Rosuvastatin Calcium,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Daewoong Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Evolocumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hyperlipoproteinemia Type II.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
December 22, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
STOCK RECAP #PipelineProspector
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
